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1st Dept. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GermanySee Article, pages 612–617Autoimmune hepatitis (AIH) is considered a rare disease. The
incidence and prevalence of AIH has been assessed in only two
studies on a population based level [1,2]. This is due to the fact
that only few countries provide reliable information on their
inhabitants diagnoses as well as their causes and date of death.
In addition, diagnosing AIH is difﬁcult, and the disease is often
misinterpreted as toxic liver injury or non-speciﬁc elevation of
liver enzymes. Even liver histology can be misleading, for exam-
ple in variant syndromes or in patients with an acute presenta-
tion [3,4]. Taking this into account, the study presented by
Grønbæk and colleagues in this issue of the journal [5] provides
some important novel information on the epidemiology of AIH
as well as on the course of the disease.
In their study, the incidence and prevalence of AIH in Den-
mark was assessed on a population level during a nearly 20 year
time period ranging from 1994 to 2013. 1721 patients with AIH
were identiﬁed. The diagnostic classiﬁcation relied on the main
diagnosis coded at hospital discharge as well as from outpatient
services. For the interpretation of their data one has to consider
the obvious drawbacks of such a registry based study design,
including the lack of chart review for the validation of the diag-
nosis, the lack of data on treatment given as well as missing infor-
mation on biochemical or histological response rates. Liver
histology had been performed in the majority of cases, but in
one quarter of cases no histology was apparently done or infor-
mation available – even though liver biopsy is considered an
essential part of making a diagnosis of AIH.
The study conﬁrms some of the previous ﬁndings on AIH
epidemiology, including the peak incidence around the age of
60–70 years, the female predominance (72% female) and the high
rate of liver cirrhosis at ﬁrst presentation (28%). The most striking
observation was the marked increase in incidence over time:
Between the years 1994 to 2012 the incidence rate of AIH in Den-
mark has nearly doubled, reaching a point prevalence in the year
2012 of 24/100.000 (35/100.000 for females). This is one of the
highest rates reported so far. The most obvious interpretationJournal of Hepatology 20
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Open access under CC BY-NC-ND license.of such a ﬁnding in a rare disease is better case ascertainment
in more recent years. However, coding practices, health care
organisation and, most importantly, the stage of disease detected
histologically remained similar over the complete time period.
This strongly argues against a relative change in case ascertain-
ment rates, and makes it very likely that these results represent
a genuine rise in AIH incidence. Increasing rates of non-liver
related autoimmune diseases such as rheumatoid arthritis [6]
have been reported repeatedly during the past years. In addition,
these novel data compare well with the marked rise in incidence
rates reported for primary biliary cirrhosis [7] and recently also
for primary sclerosing cholangitis [8], the two other autoimmune
liver diseases. The hygiene hypothesis has been cited in order to
explain the increasing incidence of autoimmune diseases in con-
trast to decreasing incidences of infectious diseases in general. In
recent years we have learned that the interaction with our gut
microbiota has a major inﬂuence on our health and especially
on the shaping and functioning of our immune system [9,10].
Therefore it could be speculated that changes in living conditions
such as diet have led to changes in the intestinal microbiota,
which in turn inﬂuences the regulation of the immune system
including the gut-liver axis.
The other worrying ﬁnding of this study is that 10 year mor-
tality was signiﬁcant. However, there is also good news from this
study: Although the incidence of AIH was found to be on the rise,
mortality from AIH seems to have decreased in Denmark. It is
unlikely that this improved prognosis was due to earlier diagno-
sis of the disease, as the proportion of patients with cirrhosis at
diagnosis remained stable throughout the study period. It is
therefore more likely that this effect is a result of improved care
and treatment of AIH in Denmark. Within the patient group, the
risk to die from AIH was increased with male gender and the
presence of liver cirrhosis at presentation. Liver cirrhosis was
more prevalent in younger and older patients, with 43% of
patients aged 10–19 years having cirrhosis at diagnosis of AIH.
It has always been the experience that paediatric AIH is more
severe than AIH in later adulthood, and the disease appears to
be dichotomous with an aggressive and rapidly progressive dis-
ease manifesting in childhood or teenage years, and a usually,
but not always, milder disease in late adulthood. Young age
and male gender have recently also been identiﬁed as risk factors
for severe disease in patients with primary biliary cirrhosis [11].
Male gender and cirrhosis were also the key risk factors for the14 vol. 60 j 478–479
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development of hepatocellular carcinoma, which occurred at a
very low rate with a 10 year cumulative incidence of only 0.7%.
6 of the 8 cases occurred in men with cirrhosis or ﬁbrosis on his-
tology. Surveillance recommendations for HCC in AIH presently
include all patients with cirrhosis, and the present data are not
sufﬁcient to change these recommendations. Nonetheless,
patients and their physicians will be reassured by the overall very
low risk of HCC in AIH, especially in women.
The study also suggests that we need to perform better in the
treatment of our patients. The considerable mortality within the
ﬁrst year after presentation (6% with two thirds of deaths liver
related) points to the fact that many patients had advanced or
highly aggressive disease at diagnosis and died in spite of treat-
ment initiation. Mortality in AIH patients remained doubled after
surviving the ﬁrst year and reached 26% after 10 years. Excellent
survival rates have been reported for AIH patients depending on
the study design and the length of observation [12,13]. However,
the standardized mortality ratio for AIH was doubled in another
recent population based study from New Zealand [14]. Several
factors such as multiple relapses, lack of remission after six
months of treatment, young age and the presence of cirrhosis
have been described as negative predictors of disease
[13,15,16]. Of particular importance in the current study is the
fact that the increased mortality was not restricted to patients
with cirrhosis. Mortality started to increase in patients initially
presenting with liver ﬁbrosis after around 9 years of treatment.
Taking the potential of histological sampling error and the lack
of follow-up data into account this suggests that the progression
of disease was not sufﬁciently controlled in these patients. These
data underline the requirement to suppress hepatic inﬂammation
and the ensuing liver ﬁbrosis in the long term. As a surrogate of
this, complete biochemical remission as deﬁned in the most
recent guidelines (normalization of serum aminotransferase lev-
els and IgG) [17] should be aimed at and the maintenance of
remission has to be veriﬁed on a regular basis.
Although per deﬁnition rare diseases, autoimmune liver dis-
eases including autoimmune hepatitis seem to be on the rise,
and morbidity and mortality due to these diseases remain signif-
icant health care problems. Even though AIH almost always
responds to initial immunosuppressive therapy, timely diagnosis,
more speciﬁc and effective treatment options and better special-
ist care for all patients is required to prevent excess deaths due to
this disease. With rising incidence and prevalence rates, the chal-
lenge is increasing for scientists and clinicians alike to elucidate
the pathogenesis of autoimmune liver diseases in order to
improve treatment options targeting disease progression as well
as quality of life.Financial support
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